Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization

Fecha de publicación:

Autores organización

Autores

  • Gill C.M.
  • Aktas E.
  • Alfouzan W.
  • Bourassa L.
  • Brink A.
  • Burnham C.-A.D.
  • Canton R.
  • Carmeli Y.
  • Falcone M.
  • Kiffer C.
  • Marchese A.
  • Martinez O.
  • Pournaras S.
  • Seifert H.
  • Thabit A.K.
  • Westblade L.F.
  • Nicolau D.P.
  • Wille J.
  • Rezende T.T.F.
  • Cekin Z.
  • Malkocoglu G.
  • Gijón D.
  • Tarakmeh L.A.
  • Chu C.Y.
  • Opperman C.J.
  • Tootla H.D.
  • Moodley C.
  • Coetzee J.
  • Vourli S.
  • Dimopoulos G.
  • Attallah D.M.
  • Tiseo G.
  • Leonildi A.
  • Giordano C.
  • Barnini S.
  • Menichetti F.
  • Di Pilato V.
  • Codda G.
  • Vena A.
  • Giacobbe D.R.
  • Satlin M.
  • Curtis L.
  • Fang F.
  • Thomson G.
  • Thomson K.

Grupos de investigación

Resumen

The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints. © 2021 American Society for Microbiology.

Datos de la publicación

ISSN/ISSNe:
0066-4804, 1098-6596

Antimicrobial Agents And Chemotherapy  American Society for Microbiology

Tipo:
Article
Páginas:
-
Enlace a otro recurso:
www.scopus.com

Citas Recibidas en Scopus: 7

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; cefepime; ceftazidime; antiinfective agent; azabicyclo derivative; carbapenem derivative; ceftazidime; cephalosporin derivative; antibiotic sensitivity; Article; bacterium isolate; carbapenem resistant Pseudomonas aeruginosa; clinical laboratory standard; controlled study; dose calculation; drug potency; in vitro study; maximum permissible dose; MIC50; MIC90; Monte Carlo method; nonhuman; process optimization; human; microbial sensitivity test; Pseudomonas aeruginosa; Pseudomonas infection

Citar la publicación

Compartir la publicación